Adverse cutaneous reactions to drugs (CDRs) at the General Teaching Hospital “Dr. Agostinho Neto”, Guantánamo 2018-2019
Keywords:
cutaneous reactions, adverse cutaneous reactions to drugs, toxicodermasAbstract
Introduction: no studies in reference to adverse cutaneous reactions to drugs (CDRs) have been found at Guantanamo, need felt by the local dermatology faculty.
Objective: characterize the adverse cutaneous reactions to drugs in patients treated at the Dermatology Service of the General Teaching Hospital "Dr. Agostinho Neto" in Guantanamo, period 2018-2019.
Method: a descriptive and transversal study was carried out with all patients (N=75) with the diagnosis of adverse cutaneous reactions to drugs referred to the Dermatology Clinic of the General Teaching Hospital "Dr. Agostinho Neto, the drug that caused the reaction, clinical diagnosis, type of reaction, time from ingestion of the drug until the symptoms appeared, number of reactions and medical behaviour were specified.
Results: These reactions were more common in patients using ibuprofen (18.7%), the most frequent clinical form was erythema multiforme minor (82.7%), above all were mild reactions (94.8%), which occurred more often at 10 ± 2.1 days of using the drug. 97.4% of patients were treated on an outpatient basis.
Conclusions: the (CDRs) does not constitute a health problem in the Dermatology Service of the General Teaching Hospital "Dr. Agostinho Neto", they present a clinical spectrum consistent with what is endorsed in the scientific literature, but it is noted that the diagnosis is not usually as early as demand, because patients usually request medical evaluation after a period exceeding seven days.
Downloads
References
2. Bouvy JC, Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: A review of recent observational studies. Drug Safety [en línea]. 2015 [citado 23 Ene 2020]; 38:437-53. Disponible en: http://refhub.elsevier.com/S0001-7310(18)30246-1/sbref0105
3. Dodiuk-Gad RP, Chung W-H, Valeyrie-Allanore L, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol [en línea]. 2015 [citado 23 Ene 2020]; 16(6):475-93.Disponible en: http://refhub.elsevier.com/S0889-8545(17)30080-3/sref17
4. Alfonso Orta I, Toledo Romaní ME, Coutín Marie G, Garcia Fariñas A, González Cruz R, Jiménez López G. Reacciones adversas a los antimicrobianos en Cuba. Rev Cubana Salud Púb [en línea]. 2016 [citado 23 Ene 2020]; 42(2):294-305. Disponible en: http://www.sld.cu/sitios/revsalud/
5. Reportes de reacciones cutáneas adversas medicamentosas de los años 2015-2017. Base de datos. Guantánamo.
6. Fernández J. Alergia básica. Barcelona: MRA Ediciones; 2015.
7. Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, et al. International consensus on drug allergy. Allergy [en línea]. 2014 [citado 23 Ene 2020]; 69:420-37.Disponible en: http://refhub.elsevier.com/S0001-7310(18)30246-1/sbref0110
8. Duvic M. Urticaria, reacciones cutáneas por hipersensibilidad a fármacos, nódulos y tumores y enfermedades atróficas[en línea]. España: Elsevier; 2017. p: 2683-2694 [citado 23 Ene 2020]. Disponible en: https://expertconsult.inkling.com
9. Sharma M, Bennett C, Cohen SN, et al. H1-antihistamines for chronic spontaneous urticaria. Cochrane Database Syst Rev[en línea]. 2014 [citado 23 Ene 2020]; (1):CD006137. DOI: 10.1002/14651858.CD006137.pub2
10. Silva-Espinosa DL, Ramírez-Zuluaga LF, Serrano-Reyes CD.Superposición de reacciones graves por fármacos. Reporte de dos casos. Rev Alerg Mex [en línea]. 2018 [citado 23 Ene 2020]; 65(Supl1):97. Disponible en: http://revistaalergia.mx/ojs/index.php/ram/article/view/477/761
11. Fricke-Galindo I, LLerena A, López-López M. An update on HLA alleles associated with adverse drug reactions. Drug Metab Pers Ther [en línea]. 2017 [citado 23 Ene 2020]; 32:73-87. Disponible en: http://crossmark.crossref.org/dialog/?doi=10.24875/RMN.19000051&domain=pdf
12. Park HJ, Kim SR, Leem DW, Gearing M. Clinical features of and genetic predisposition to drug-induced stevens-johnson syndrome and toxic epidermal necrolysis in a single Korean tertiary institution patients-investi-gating the relation between the HLA-B*4403 allele and lamotrigine. Eur J Clin Pharmacol [en línea]. 2015[citado 23 Ene 2020]; 71(1):35-41.DOI: 10.1007/s00228-014-1764-0
13. Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. Lancet [en línea]. 2017 Oct [citado 23 Ene 2020]; 390(10106):1996-2011. DOI: 10.1016/S0140-6736(16)30378-6
14. Jiménez López G, García Fariñas A, Gálvez González AM, Alfonso Orta I, Lara BastanzuriMC, Calvo Barbado DM. Medicamentos notificados como productores de reacciones adversas graves en Cuba en un período de diez años. Rev Cubana Salud Púb [en línea]. 2014 [citado 23 Ene 2020]; 40(4):263-275. Disponible en: http://scielo.sld.cu/pdf/rcsp/v40n4/spu03414.pdf
15. Begoña Cueva C, Carretero Ares JL, González Delgado P, Fernández Sánchez J. Reacciones alérgicas a fármacos. Abordaje en atención primaria y en el hospital. FMC [en línea]. 2017 Jun-Jul [citado 23 Ene 2020]; 24(6):303-11. Disponible en: https://www.fmc.es/es-reacciones-alergicas-farmacos-abordaje-atencion-articulo-S1134207217300580
